An observational study in Cutaneous Wounds, sponsored by RedDress Ltd.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-29.
Sponsored by RedDress Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Multicenter observational study to explore the efficacy of ActiGraft in the treatment of exuding cutaneous wounds in real-life usage.
2,221 studies on the registry are indexed under Wounds and Injuries; 442 are open to participants now.
This study's planned enrollment of 500 is above the median of 169 across 690 observational studies indexed under Wounds and Injuries.
Browse Wounds and Injuries studies →RedDress Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with all types of exuding cutaneous wound
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Whole blood clot (WBC) gel
Device: ActiGraft
Whole blood clot (WBC) gel
Percentage area reduction (PAR) at 4 weeks
Change from baseline at 4 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).
Time frame: 4 weeks
Nature, frequency, and severity of adverse events in the intent to treat population
Nature, frequency, and severity (by CTCAE5) of adverse events
Time frame: 1 year
Percentage area reduction at 8 and 12 weeks
Change from baseline at 8 and 12 weeks of wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT).
Time frame: 12 weeks
Reduction in pain at 4 weeks
Pain reduction at 4 weeks for wounds treated with ACTIGRAFT compared to other treatments (no ACTIGRAFT) for patients reporting any level of wound related pain (\>1 on a VAS scale of 0-10 points) at baseline
Time frame: 4 weeks
Plan to share: Yes — The results will be part of several scientific publications
Supporting information: Study protocol
Time frame: Upon publication
Started Feb 2019 (actual). Primary completion is estimated for Jul 2026, 88 months after the start.
Of 47 industry-sponsored observational studies under Wounds and Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 63. This study's planned 88 months is above that.
Counting every sponsor, half of 312 studies reached it within 28 months; a quarter within 12 and three quarters within 60.
Wounds and Injuries covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
RedDress Ltd.